Business
Arecor Presents Positive Data for AT278 at EASD
Arecor Presents Positive Data for AT278 at EASD.
About this update from Arecor Therapeutics Plc
[{"type":"text","content":"\n \n \n \n Arecor Therapeutics plc\n \n \n \n (\"Arecor\", the \"Company\" or the \"Group\")\n \n \n \n \n \n \n \n \n ARECOR PRESENTS DATA FROM POSITIVE PHASE I CLINICAL TRIAL OF\nAT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN FOR DIABETES AT EASD 2022\n \n \n \n \n \n \n \n \n - Delivers significantly accelerated absorption of insulin compared to gold standard, NovoRapid®(100U/mL), even with a 5-fold increase in concentration\n \n \n - Potential to significantly improve post prandial glucose control and reduce number of daily injections for people with diabetes who have high insulin needs\n \n \n - Critical enabler in development of\n \n next generation miniaturised insulin-delivery systems\n \n \n \n - Favourable safety profile with no safety signals detected\n \n \n \n \n \n \n Cambridge, UK,\n \n 20 September 2022. Arecor Therapeutics plc (AIM: AREC),the biopharmaceutical company advancing today's therapies to enable healthier lives, today presents positive results from the Phase I clinical trial of its ultra-rapid acting, ultra-concentrated insulin product candidate, AT278, at the European Association for the Study of Diabetes (EASD) Annual Meeting. \n \n \n \n \n The abstract, \"\n Phase I study investigating PK and PD of highly-concentrated insulin aspart AT278 U500\n \",\n is being presented as part of the Short Oral Discussion Session A, \"How complicated is type 1 diabetes?\" (11:45-12:45 CEST).\n \n \n \n \n \n AT278 is Arecor's ultra-concentrated (500 U/mL), ultra-rapid acting insulin candidate, formulated using the Company's ArestatTM technology and designed to significantly accelerate insulin absorption post injection to enable more effective and convenient management of blood glucose levels in people with high daily insulin requirements.\n \n \n \n \n \n \n \n \n Dr Thomas Pieber, investigator for the ARE-278-102 study, Professor of Medicine, Head of the Division of Endocrinology and Metabolism and Chairman of the Department of Internal Medicine, Medical University of Graz, Austria, said:\n \n \n \"The rapid-acting characteristics of AT278,\n even with its 5-fold increase in concentration,\n are clinically significant, suggesting that AT278 has the potential to\n significantly improve post prandial glucose control and reduce the number of dail...